Skip to main content
eXit

ImmunoSensation leaves X

Due to recent developments, we decided to discontinue our activities on the social media plattform X. With this decision, we follow more than 60 german universities and other research institutions. As a Cluster of Excellence, we see the communication of research and scientific results as well as their discussion as one of our tasks, which is why we did not make this decision lightly. However, X's line is not compatible with the basic values that we represent and also want to live in our communication. These include transparency, constructive discourse and, above all, scientific integrity.

We are looking forward to welcome you on our channels at

Bluesky

LinkedIn

Instagram

facebook

youtube

 

Related news

Dr. Ivana Jorgacevic und Prof. Dr. Rayk Behrendt have discovered that the inflammatory messenger substance interferon-alpha can trigger Sjögren's syndrome: The researchers in Bonn.

Publication

New test points to precision treatment for autoimmune condition

—Interferon alpha is an inflammatory mediator that can cause Sjögren’s syndrome, an autoimmune disease. This is revealed in a recent study carried out by the University Hospital Bonn together with the University of Bonn, the University of Edinburgh and Newcastle University. Their findings, which have been published in the journal “Lancet Rheumatology,” could make it easier in the medium term to develop drugs to fight this chronic condition.
View entry
Prof. Dr. Elvira Mass (left) and Prof. Dr. Tatjana Tchumatchenko (right)

Honors & Funding

Hunting for New Angles

—New research questions often arise where different methods, mindsets and subject-specific cultures meet, and it is these kinds of encounter that Professor Elvira Mass and Professor Tatjana Tchumatchenko want to make happen in a targeted way in future. The two researchers have been picked as Henriette Herz Scouts by the Alexander von Humboldt Foundation.
View entry
Precise Konsortium

Publication Honors & Funding

Making Cancer Cells More Predictable: PRECISE Aims to Forecast Therapeutically Actionable Vulnerabilities

—Which genes and signaling pathways does a cancer cell require to survive? And which of these could serve as therapeutic targets? The pan-European initiative PRECISE aims to identify such vulnerabilities not only through labor-intensive laboratory experiments but also by predicting them using computational models. The UKB and the University of Bonn, represented by Prof. Dr. Maximilian Billmann and Prof. Dr. Jonathan Schmid-Burgk, are among the founding partners of the consortium. The scientific vision of the initiative has now been published in a commentary in Nature Genetics.
View entry

Back to the news overview